Abstract

Day One Biopharmaceuticals Inc. will report fiscal fourth-quarter 2025 results on February 24, 2026, Post Market; this preview summarizes expected revenue, margins, and adjusted EPS trends and synthesizes the majority institutional stance ahead of the release.

Market Forecast

Consensus-derived projections for Day One Biopharmaceuticals Inc.’s current quarter point to revenue of $47.60 million (estimateYoyGrowth 71.29%), EBIT of -$23.89 million (estimateYoyGrowth 42.19%), and adjusted EPS of -$0.16 (estimateYoyGrowth 55.80%), with gross margin and net margin expected to remain influenced by commercialization spend; YoY values are interpreted as decimal ratios. The company’s main business is product sales, with licenses contributing modestly; product revenue remains the highlight as Ojemda commercialization scales, while the most promising segment is product sales at $38.52 million last quarter, up strongly YoY and positioning for further growth.

Last Quarter Review

Day One Biopharmaceuticals Inc. delivered revenue of $39.80 million, a gross profit margin of 88.74%, GAAP net profit attributable to the parent company of -$19.73 million with quarter-on-quarter change rendered as 34.94%, a net profit margin of -49.57%, and adjusted EPS of -$0.19, reflecting actualYoYGrowth of 48.65%. The key highlight was outperformance versus the prior estimate: revenue surprised positively by $1.59 million while EPS beat by $0.103, supported by disciplined operating expenses and expanding gross margin anchored by Ojemda sales. Main business momentum came from product revenue of $38.52 million (approximately 96.80% of total) and license revenue of $1.27 million (about 3.20%), underscoring continued uptake of the commercial portfolio.

Current Quarter Outlook

Core Commercial Business: Product Sales

Product sales remain the primary revenue engine for Day One Biopharmaceuticals Inc. and are expected to continue expanding as market penetration improves and prescriber adoption broadens. The last quarter’s product revenue of $38.52 million accounted for roughly 96.80% of total revenue, indicating a heavily concentrated revenue mix that amplifies the impact of commercial execution. For the current quarter, the revenue estimate of $47.60 million implies robust year-over-year growth of 71.29%, with gross margin likely supported by the high contribution from product sales and limited cost of goods typical for small-molecule oncology therapies. Management’s commercialization activities, such as expanded sales coverage and patient support programs, are poised to drive sequential demand, although investments in market access and awareness may offset near-term operating leverage.

Growth Optionality: Emerging License and Collaboration Income

License revenue contributed $1.27 million last quarter, representing 3.20% of total, and while smaller in magnitude, it offers optionality from milestones or collaboration structures. In the near term, the forecasted revenue mix suggests product sales will remain the predominant growth lever, but incremental license income could smooth quarter-to-quarter variability and help fund pipeline execution. As the company advances ongoing clinical programs, potential out-licensing or co-development arrangements may create non-dilutive cash inflows, though timing is inherently uncertain and modeled conservatively. If additional agreements materialize, EBIT and EPS could see upside from higher-margin recognition associated with milestones.

Stock Price Drivers This Quarter

Three factors are most likely to influence the stock around the earnings print: top-line trajectory versus the $47.60 million estimate, operating expense discipline that shapes EBIT and adjusted EPS, and any qualitative updates on commercialization sustainability. A revenue print at or above the estimate would validate ongoing demand trends and likely reinforce confidence in the near-term growth path. On profitability metrics, the EBIT estimate of -$23.89 million and adjusted EPS estimate of -$0.16 reflect continuing investment intensity; tighter spending or earlier-than-expected operating leverage could catalyze sentiment if margins improve faster than modeled. Commentary on payer dynamics, treatment adoption curves, and potential geographic expansion will be parsed closely to assess durability of demand and inform expectations for subsequent quarters.

Analyst Opinions

Bullish views dominate recent institutional commentary on Day One Biopharmaceuticals Inc., with multiple firms reiterating Buy or Overweight ratings and emphasizing commercial momentum and pipeline visibility. J.P. Morgan’s Anupam Rama has maintained an Overweight stance, citing outperformance of Ojemda and pipeline progress that supports revenue durability and scale-up potential. JonesTrading’s Soumit Roy has reaffirmed a Buy rating, highlighting promising long-term data from FIREFLY-1 and reinforcing confidence in demand dynamics for the commercial franchise; JonesTrading’s target of $26.00 underscores the constructive view on execution into the current quarter. H.C. Wainwright’s Andres Y. Maldonado also reiterated a Buy rating with a defined price target, pointing to positive commercialization trends and the potential for clinical catalysts to enhance the medium-term revenue profile. The majority perspective centers on expectations that the company will meet or exceed the $47.60 million revenue estimate, maintain a high gross margin consistent with last quarter’s 88.74%, and show incremental progress toward operating leverage, even as EBIT remains negative due to continued investment. These analysts view near-term performance as a step in a longer trajectory of scaling product sales and maturing margins, with upcoming clinical readouts and broader market adoption acting as supportive tailwinds.